MGI Tech and Universidad de San Martín de Porres Forge Alliance to Advance Genetic Research in Peru

MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, announced a partnership with...

December 02, 2024 | Monday | News
Aulos Bioscience Doses First Patient in Phase 2 Trial for Second-Line PD-L1+ NSCLC Treatment

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, tod...

November 29, 2024 | Friday | News
European Commission Approves TEVIMBRA® for First-Line Treatment of Esophageal and Gastric Cancers

 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, announced ...

November 28, 2024 | Thursday | News
President-elect Trump Nominates Jay Bhattacharya to Lead NIH in Major Health Policy Shift

    President-elect Donald Trump has nominated Dr. Jay Bhattacharya, a Stanford physician and economist, as the next director of the Nation...

November 27, 2024 | Wednesday | News
Hovione Expands Global Footprint with Major Investments in U.S. and Europe

    Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, just completed significant expansions in...

November 27, 2024 | Wednesday | News
Acadia Pharmaceuticals Licenses SAN711 from Saniona for Essential Tremor, Expanding Neurology Pipeline

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the develo...

November 27, 2024 | Wednesday | News
Amgen Announces Promising Phase 2 Results for MariTide, Showing Significant Weight Loss and Cardiometabolic Improvements

Amgen (NASDAQ:AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly...

November 27, 2024 | Wednesday | News
Alnylam's Vutrisiran sNDA Accepted by FDA for Priority Review in ATTR-CM with March 2025 Decision Expected

 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration&n...

November 26, 2024 | Tuesday | News
GSK’s Blenrep Combination Therapy Accepted for FDA Review in Relapsed Multiple Myeloma

GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep&...

November 26, 2024 | Tuesday | News
MSD Announces Positive Phase 3 ZENITH Study Results for WINREVAIR in Pulmonary Arterial Hypertension

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 ZENITH study evaluating WINREV...

November 26, 2024 | Tuesday | News
Halozyme Withdraws €2.0 Billion Acquisition Proposal for Evotec Amid Lack of Engagement

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: ...

November 25, 2024 | Monday | News
DANNCE.AI Secures $2.6M Pre-Seed Funding to Transform Neurological Care with AI-Powered Movement Analysis

DANNCE.AI raised $2.6 million in pre-seed funding led by LDV Capital, following initial investment from Glasswing Ventures, with participation from The L...

November 22, 2024 | Friday | News
Zevra Therapeutics Launches MIPLYFFA™, the First FDA-Approved Treatment for Niemann-Pick Disease Type C

MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist&...

November 22, 2024 | Friday | News
Avirmax Biopharma Doses First Patient in Phase I/IIa Trial of ABI-110, Pioneering Gene Therapy for Wet AMD and PCV

Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, announced that the first patient has been successfully dosed in the Phas...

November 22, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close